SLDB Solid Biosciences Inc

$SLDB Back on the 200-day. This one matters. Solid Bio has been bleeding off the July high (~$11.40), and the Sept bounce stalled at a lower high near $10.45. The last two sessions took out the 50-day ($8.91) and 100-day ($8.46). Today it closed at $7.48 (−6.73%), 7 cents under the rising 200-day ($7.55). That 200-day has been the floor since the stock reclaimed it in Dec. It was tested in Jan, Feb, Mar, and May, and every tap got bought. A 7-cent close under it on one day isn't a breakdown. It needs follow-through. Until then it's a test, not a verdict. Tell of the tape: the intraday low was $7.35. S-1 sits at $7.34. Buyers stepped in to the penny. Levels I'm watching: • S-1: $7.00–$7.34, today's low and the first shelf • S-2: $6.00–$6.34, the May retest of the 200-day • S-3: $5.24, the Dec/Jan base Momentum: Stochastics at 12.56 is oversold. RSI at 33.55 is close, but not there. ADX is 21.48 and rising, with −DI at 37.57 against +DI at 13.93. Sellers are in control and the trend is gaining strength. In a small-cap biotech tape, oversold can stay oversold for a while. No capitulation volume either. 1.35M today is not the kind of flush that usually marks a low. Bottom line: a reclaim of $7.55, then $8.00+, and this is just another 200-day hold. If it fails to reclaim, S-1 gives way and $6.00–$6.34 is in play. No position. Just reading the chart. Do your own work.

$SLDB ... this is back in my buying zone for sure..... one of my Gene Therapy bets that have for a long time held various levels of stock in...

nobody is talking about $SLDB yet and that's the part I like UBS just started coverage at Buy with a $20 target and the stock closed Friday at $5.53. SGT 003 for Duchenne, 50 plus patients dosed already, and the street is basically all Buy ratings here. FDA meeting around the turn of the year. quiet names don't stay quiet into a catalyst like that

$SLDB UBS initiates Solid Bio with a Buy and $20 PT. Analyst Joon Lee highlights Solid's lead DMD gene therapy candidate SGT-003, arguing the market is heavily discounting its commercial potential... modeling $3.2B in 2035 unadjusted peak sales (vs. $2.8B consensus). Added another piece on today's flush. Building a nice position here and letting the fundamental thesis play out over time while broader biotech washes out weak hands.

$SLDB down another 13% today. Our S-2 cracked, and price flushed straight into the $5 handle target... as mapped below. Sector sentiment in biotech is absolute capitulation rn, but this is precisely when deep fundamental DD matters most, IMO. Picked up 1/2 position between $5.75 - $5.88. Extremely familiar with this name, so happy to accumulate quality at multi-month support while others puke shares. Will add to full size as things materialize and on additional confirmation. Giddy up!

$SLDB 25.6% net decline in outstanding short positions, consistent with substantial short covering! 4.4m! Shorts, better cover otherwise you’re gonna get slaughtered! Imho plz do dd!

$SLDB I sold at 6.20 (92% gain) a couple of months ago and thought I would back in at 6.50. Who would have thought...

$SLDB Volatility Expectations: Biotech stocks heading into FDA meetings typically experience increased volume and volatility as institutional position-building occurs in advance of the readout or meeting minutes. Imho